25-Hydroxyvitamin D and TSH as Risk Factors or Prognostic Markers in Thyroid Carcinoma

Imagem de Miniatura
Arquivos
art_DANILOVIC_25Hydroxyvitamin_D_and_TSH_as_Risk_Factors_or_2016.PDF (1.15 MB)
Citações na Scopus
24
Tipo de produção
article
Data de publicação
2016
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
PUBLIC LIBRARY SCIENCE
Autores
Citação
PLOS ONE, v.11, n.10, article ID e0164550, 12p, 2016
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Objective The increasing incidence of thyroid nodules demands identification of risk factors for malignant disease. Several studies suggested the association of higher TSH levels with cancer, but influence of 25-hydroxyvitamin D (25OHD) is controversial. This study aimed to identify the relationship of thyroid cancer with higher TSH levels and hypovitaminosis D and to evaluate their influence on prognostic characteristics of papillary thyroid carcinomas (PTC). Methods We retrospectively evaluated 433 patients submitted to thyroidectomy for thyroid nodules. Patients were categorized according to quartiles of TSH and 25OHD levels. Clinicopathological features were analyzed. Results Subjects with thyroid carcinomas were more frequently male and younger compared to those with benign disease. Their median TSH levels were higher and adjusted odds-ratio (OR) for cancer in the highest-quartile of TSH (> 2.4 mUI/mL) was 2.36 (1.36-4.09). Although vitamin D deficiency/insufficiency was prevalent in our cohort (84%), no significant differences in 25OHD levels or quartile distribution were observed between benign and malignant cases. Among 187 patients with PTC, analyses of prognostic features revealed increased risk of lymph nodes metastases for subjects with highest-quartile TSH levels (OR = 3.7, p = 0.029). Decreased 25OHD levels were not overtly associated with poor prognosis in PTC. Conclusions In this cross-sectional cohort, higher TSH levels increased the risk of cancer in thyroid nodules and influenced its prognosis, particularly favoring lymph nodes metastases. On theother hand, no association was found between 25OHD levels and thyroid carcinoma risk or prognosis, suggesting that serum 25OHD determination may not contribute to risk assessment workup of thyroid nodules.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/16980
Referências
  1. ABE E, 1981, P NATL ACAD SCI-BIOL, V78, P4990, DOI 10.1073/pnas.78.8.4990
  2. Ahn HY, 2016, THYROID, V26, P429, DOI 10.1089/thy.2015.0516
  3. Akslen LA, 1998, BRIT J CANCER, V77, P1174, DOI 10.1038/bjc.1998.195
  4. Bade B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112863
  5. Bauer SR, 2013, MEDICINE, V92, P123, DOI 10.1097/MD.0b013e3182943bc2
  6. Ben-Shoshan M, 2007, MOL CANCER THER, V6, P1433, DOI 10.1158/1535-7163.MCT-06-0677
  7. Bises G, 2004, J HISTOCHEM CYTOCHEM, V52, P985, DOI 10.1369/jhc.4B6271.2004
  8. Blutt SE, 2000, ENDOCRINOLOGY, V141, P10, DOI 10.1210/en.141.1.10
  9. Chailurkit LO, 2013, THYROID, V23, P25, DOI 10.1089/thy.2012.0001
  10. Chen W, 2007, BRIT J CANCER, V97, P123, DOI 10.1038/sj.bjc.6603834
  11. Chlebowski RT, 2008, J NATL CANCER I, V100, P1581, DOI 10.1093/jnci/djn360
  12. Chung KW, 2006, CLIN ENDOCRINOL, V65, P660, DOI 10.1111/j.1365-2265.2006.02646.x
  13. Cipriani C, 2014, INT J ENDOCRINOL, V2014, DOI [10.1155/2014/841248, DOI 10.1155/2014/841248]
  14. EISMAN JA, 1979, LANCET, V2, P1335
  15. Feldman D, 2014, NAT REV CANCER, V14, P342, DOI 10.1038/nrc3691
  16. Fiore E, 2009, ENDOCR-RELAT CANCER, V16, P1251, DOI 10.1677/ERC-09-0036
  17. Fraser A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013882
  18. GARLAND CF, 1989, LANCET, V2, P1176
  19. Gilbert R, 2011, CANCER CAUSE CONTROL, V22, P319, DOI 10.1007/s10552-010-9706-3
  20. Gissel T, 2008, J STEROID BIOCHEM, V111, P195, DOI 10.1016/j.jsbmb.2008.06.002
  21. Greene FL, 2002, AJCC CANC STAGING MA
  22. Haugen B. R., 2015, THYROID, DOI [10.1089/thy.2015.0020, DOI 10.1089/THY.2015.0020]
  23. Haymart MR, 2009, CLIN ENDOCRINOL, V71, P434, DOI 10.1111/j.1365-2265.2008.03489.x
  24. HOELTING T, 1993, BIOCHEM BIOPH RES CO, V195, P1230, DOI 10.1006/bbrc.1993.2176
  25. Holick MF, 2008, AM J CLIN NUTR, V87, p1080S
  26. Holick MF, 2011, J CLIN ENDOCR METAB, V96, P1911, DOI 10.1210/jc.2011-0385
  27. Hsieh TC, 1996, BIOCHEM BIOPH RES CO, V223, P141, DOI 10.1006/bbrc.1996.0859
  28. Hughes DT, 2011, THYROID, V21, P231, DOI 10.1089/thy.2010.0137
  29. Izkhakov E, 2016, J STEROID BIOCHEM, V159, P26, DOI 10.1016/j.jsbmb.2016.02.016
  30. Jonklaas J, 2013, THYROID, V23, P1079, DOI 10.1089/thy.2012.0548
  31. Jonklaas J, 2006, THYROID, V16, P1229, DOI 10.1089/thy.2006.16.1229
  32. Kim JR, 2014, THYROID, V24, P1618, DOI 10.1089/thy.2014.0090
  33. Kim SS, 2011, ENDOCRINE, V39, P259, DOI 10.1007/s12020-010-9430-5
  34. Kmiec P, 2015, EXP CLIN ENDOCR DIAB, V123, P386, DOI 10.1055/s-0035-1554714
  35. Krishnan AV, 2010, ENDOCRINOLOGY, V151, P32, DOI 10.1210/en.2009-0855
  36. Laney N, 2010, INT J ENDOCRINOL, V2010, DOI [10.1155/2010/805716, DOI 10.1155/2010/805716]
  37. Lee HJ, 2014, CANCER-AM CANCER SOC, V120, P521, DOI 10.1002/cncr.28368
  38. Lee JE, 2011, CANCER PREV RES, V4, P735, DOI 10.1158/1940-6207.CAPR-10-0289
  39. Leyssens C, 2013, ENDOCR-RELAT CANCER, V20, pR31, DOI 10.1530/ERC-12-0381
  40. Li MA, 2014, J CLIN ENDOCR METAB, V99, P2327, DOI 10.1210/jc.2013-4320
  41. McLeod DSA, 2012, J CLIN ENDOCR METAB, V97, P2682, DOI 10.1210/jc.2012-1083
  42. Mithal A, 2009, OSTEOPOROSIS INT, V20, P1807, DOI 10.1007/s00198-009-0954-6
  43. Morand Gregoire B, 2014, Front Oncol, V4, P309, DOI 10.3389/fonc.2014.00309
  44. Moreno J, 2005, CANCER RES, V65, P7917, DOI 10.1158/0008-5472.CAN-05-1435
  45. Muenstedt K, 2010, BREAST CARE, V5, P383, DOI 10.1159/000322651
  46. O'Grady TJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110886
  47. Palmer HG, 2001, J CELL BIOL, V154, P369, DOI 10.1083/jcb.200102028
  48. Peppone LJ, 2012, ANN SURG ONCOL, V19, P2590, DOI 10.1245/s10434-012-2297-3
  49. Pereira F, 2012, ENDOCR-RELAT CANCER, V19, pR51, DOI 10.1530/ERC-11-0388
  50. Ray R, 2012, ANTICANCER RES, V32, P727
  51. Roskies M, 2012, J OTOLARYNGOL-HEAD N, V41, P160, DOI 10.2310/7070.2011.110174
  52. Ross AC, 2011, J CLIN ENDOCR METAB, V96, P53, DOI 10.1210/jc.2010-2704
  53. Sahin M, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0589-5
  54. Shin DY, 2014, ENDOCR-RELAT CANCER, V21, P715, DOI 10.1530/ERC-14-0259
  55. SKOWRONSKI RJ, 1993, ENDOCRINOLOGY, V132, P1952, DOI 10.1210/en.132.5.1952
  56. Stepien T, 2010, ARCH MED RES, V41, P190, DOI 10.1016/j.arcmed.2010.04.004
  57. Swami S, 2016, ENDOCR-RELAT CANCER, DOI [10.1530/ERC-15-0557, DOI 10.1530/ERC-15-0557]
  58. Tuohimaa P, 2004, INT J CANCER, V108, P104, DOI 10.1002/ijc.11375
  59. Unger MD, 2010, CLIN NUTR, V29, P784, DOI 10.1016/j.clnu.2010.06.009
  60. Vimaleswaran KS, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001383
  61. Wang LL, 2004, J STEROID BIOCHEM, V89-90, P127, DOI 10.1016/j.jsbmb.2004.03.091

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCG
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/18
Artigos e Materiais de Revistas Científicas - LIM/25
Artigos e Materiais de Revistas Científicas - LIM/28
Carregar mais